Improve Human Health to Preserve Patients’ Dignity

Leading the advancement of innovative therapies in genitourinary tumors and women's health

Highlights

Asieris Pharmaceuticals Releases 2025 Semi-Annual Report with Sustained Commercial Momentum and Breakthrough Innovation Poised for Launch

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Core Areas

Urologic Oncology

Integrated diagnosis and treatment, reinforced by strengthened leadership

Women's Health

Building a robust and tiered gynecology pipeline with game-changing products

Breast and Gynecologic Oncology

Synergizing in-house R&D and licensing to cover both early- and late-stage needs

Global Partnership

News & Updates

August 28, 2025

Asieris Pharmaceuticals Releases 2025 Semi-Annual Report with Sustained Commercial Momentum and Breakthrough Innovation Poised for Launch

Asieris’ APL-1702 NDA Advances to Second Round of Technical Review

Asieris’ New Drug APL-1401 Demonstrates Positive Preliminary Results in Phase Ib Clinical Trial for Moderately-to-Severely Active UC

19th International Photodynamic Association CongressConcludes Successfully

Asieris to Present World’s Innovative Photodynamic Products at 19th IPA Congress

Asieris and Subsidiary Baylink Present Study Results on AI Small Molecules and ADC Platform at the 2025 AACR Annual Meeting

Technology Platform